StockWatch
·

Windlas Biotech Ltd

BSE: 543329

values in crores

Revenue & Profit Trend

in crores
RevenueExpenditureNet Profit
-18.5878.29175.16272.03Q2 FY2025Q3 FY2025Q4 FY2025Q1 FY2026Q2 FY2026Q3 FY2026Q4 FY2026

Margin Trend

percentage
OPM %NPM %
2.706.5210.3414.16Q2 FY2025Q3 FY2025Q4 FY2025Q1 FY2026Q2 FY2026Q3 FY2026Q4 FY2026
PeriodQ4 FY2026Q3 FY2026Q2 FY2026Q1 FY2026Q4 FY2025Q3 FY2025Q2 FY2025
INCOME
Revenue238.50+2.3%233.10+4.8%222.40+5.9%210.09+3.6%202.71+3.9%195.02+4.3%187.00
Other Income4.40-2.7%4.52+24.1%3.65-30.4%5.24+6.0%4.94+32.4%3.73-22.9%4.84
Total Income242.90+2.2%237.62+5.1%226.04+5.0%215.33+3.7%207.65+4.5%198.75+3.6%191.84
EXPENSES
Expenditure222.74+2.3%217.70+7.5%202.46+5.4%192.07+2.8%186.82+4.5%178.78+4.2%171.56
Tax4.15-16.6%4.97-14.1%5.79+3.5%5.59+23.1%4.54-4.2%4.74+2.5%4.63
PROFIT
PBT20.16+1.2%19.92-15.5%23.59+1.4%23.26+11.7%20.83+4.3%19.97-1.6%20.29
Net Profit16.02+7.1%14.95-16.0%17.80+0.8%17.66+8.5%16.29+6.9%15.23-2.8%15.66
KEY METRICS
OPM %10.58%+0.12pp10.46%-2.38pp12.84%+0.21pp12.63%+0.03pp12.60%+8.58pp4.02%-0.17pp4.19%
NPM %6.59%+0.30pp6.29%-1.58pp7.87%-0.33pp8.20%+0.36pp7.84%+0.18pp7.66%-0.50pp8.16%
EPS7.60+7.2%7.09-16.4%8.48+0.6%8.43+8.5%7.77+6.6%7.29-2.7%7.49

Corporate Events

Board MeetingWINDLAS*
2026
21May

Board Meeting

The board meeting is scheduled to consider and approve the a…

BSE Filing
Board MeetingWINDLAS*
2025
12Aug

Board Meeting

Consider and approve Notice of the Board Meeting, un-audited…

BSE Filing
DividendWINDLAS*
2025
21Jul

₹5.8 / share

BSE Filing
DividendWINDLAS*
2024
31May

₹5.5 / share

BSE Filing
DividendWINDLAS*
2024
21May

₹5.5 / share

BSE Filing
Board MeetingWINDLAS*
2024
20May

Board Meeting

Consider and approve the audited standalone and consolidated…

BSE Filing
Board MeetingWINDLAS*
2024
8Feb

Board Meeting

Consider and approve un-audited standalone and consolidated …

BSE Filing
Board MeetingWINDLAS*
2023
8Nov

Board Meeting

Consider and approve the un-audited standalone and consolida…

BSE Filing
Board MeetingWINDLAS*
2023
8Aug

Board Meeting

Consider and approve un-audited standalone and consolidated …

BSE Filing